sepsis

The Stanford spinout has launched an infectious disease test that sequences cell-free pathogen DNA to diagnose sepsis in immunocompromised patients.

Clinicians identifying and treating S. aureus bloodstream infections reduced the median length of stay by 5.6 days and hospital cost by $13,341 per patient after using Luminex's assay.

A proof-of-concept version of the method takes less than eight hours to perform ID-AST directly from whole blood. 

Formerly known as SlipChip Corp, the firm has recently won nearly $10 million in funding to hone its approaches to sepsis and CT/NG testing.

Collaborators said that the test is accurate and reliable for the rapid detection of the most common gram-positive bacteria responsible for bloodstream infections.